obesity drug news today glp-1 september 29 2025 There's lots going on this month at FDA in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Warning Letters Pharma Giants Bet on Next-Generation

But the biological plausibility is sound, and some clinicians are incorporating this strategy into their long-term GLP-1 treatment plans

GLP-1s for Cancer Prevention Because population studies are observational, they cant prove that GLP-1s lower cancer risk

However, a long-term exploratory RCT in 150 people with obesity found that differences in eating disorders psychopathology scores were not maintained at 52 weeks when liraglutide in combination with behavioral therapy was compared with behavioral therapy alone 215

Patient and public involvement This study investigated a well defined research question on a potential adverse event of GLP1 receptor agonists that is broadly recognised for its potential impact on patients, and that has been raised as a drug safety concern by drug regulatory agencies